157 related articles for article (PubMed ID: 34552943)
21. Use of mycophenolate mofetil for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database.
Funatogawa T; Narita Y; Tamura A; Mii K; Sugitani Y; Uchida T
Mod Rheumatol; 2022 Jul; 32(4):755-760. PubMed ID: 34850080
[TBL] [Abstract][Full Text] [Related]
22. Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort.
Hoffmann-Vold AM; Fretheim H; Halse AK; Seip M; Bitter H; Wallenius M; Garen T; Salberg A; Brunborg C; Midtvedt Ø; Lund MB; Aaløkken TM; Molberg Ø
Am J Respir Crit Care Med; 2019 Nov; 200(10):1258-1266. PubMed ID: 31310156
[No Abstract] [Full Text] [Related]
23. Clinical Features of Idiopathic Interstitial Pneumonia with Systemic Sclerosis-Related Autoantibody in Comparison with Interstitial Pneumonia with Systemic Sclerosis.
Yamakawa H; Hagiwara E; Kitamura H; Yamanaka Y; Ikeda S; Sekine A; Baba T; Iso S; Okudela K; Iwasawa T; Takemura T; Kuwano K; Ogura T
PLoS One; 2016; 11(8):e0161908. PubMed ID: 27564852
[TBL] [Abstract][Full Text] [Related]
24. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.
Olson AL; Maher TM; Acciai V; Mounir B; Quaresma M; Zouad-Lejour L; Wells CD; De Loureiro L
Adv Ther; 2020 Jul; 37(7):3292-3298. PubMed ID: 32451950
[TBL] [Abstract][Full Text] [Related]
25. Clinical burden and healthcare resource utilization associated with managing transfusion-dependent β-thalassemia in France.
Baldwin J; Udeze C; Li N; Boulmerka L; Dahal L; Pesce G; Quignot N; Jiang H; Galactéros F
Curr Med Res Opin; 2024 Jun; ():1-11. PubMed ID: 38873781
[No Abstract] [Full Text] [Related]
26. Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease.
Volkmann ER; Saggar R; Khanna D; Torres B; Flora A; Yoder L; Clements PJ; Elashoff RM; Ross DJ; Agrawal H; Borazan N; Furst DE; Saggar R
Arthritis Rheumatol; 2014 Jul; 66(7):1900-8. PubMed ID: 24729406
[TBL] [Abstract][Full Text] [Related]
27. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
Front Immunol; 2020; 11():1990. PubMed ID: 33013852
[TBL] [Abstract][Full Text] [Related]
28. Characteristics and risk factors of mortality in patients with systemic sclerosis-associated interstitial lung disease.
Jang HJ; Woo A; Kim SY; Yong SH; Park Y; Chung K; Lee SH; Leem AY; Lee SH; Kim EY; Jung JY; Kang YA; Kim YS; Park MS
Ann Med; 2023 Dec; 55(1):663-671. PubMed ID: 37074318
[TBL] [Abstract][Full Text] [Related]
29. Incidence, prevalence and long-term progression of Goh algorithm rated interstitial lung disease in systemic sclerosis in two independent cohorts in flanders: A retrospective cohort study.
Vandecasteele E; Melsens K; Vanhaecke A; Blockmans D; Bonroy C; Carton C; Deschepper E; De Keyser F; Houssiau F; Piette Y; Vanthuyne M; Verbeke K; Westhovens R; Wuyts WA; De Langhe E; Brusselle G; Smith V
Semin Arthritis Rheum; 2021 Oct; 51(5):969-976. PubMed ID: 34403812
[TBL] [Abstract][Full Text] [Related]
30. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.
Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y
Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031
[TBL] [Abstract][Full Text] [Related]
31. Influence of interstitial lung disease on outcome in systemic sclerosis: a population-based historical cohort study.
Bauer PR; Schiavo DN; Osborn TG; Levin DL; St Sauver J; Hanson AC; Schroeder DR; Ryu JH
Chest; 2013 Aug; 144(2):571-577. PubMed ID: 23450327
[TBL] [Abstract][Full Text] [Related]
32. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity.
Michelfelder M; Becker M; Riedlinger A; Siegert E; Drömann D; Yu X; Petersen F; Riemekasten G
Clin Rheumatol; 2017 Feb; 36(2):381-390. PubMed ID: 28028682
[TBL] [Abstract][Full Text] [Related]
33. Severity and features of frailty in systemic sclerosis-associated interstitial lung disease.
Guler SA; Kwan JM; Winstone TA; Milne KM; Dunne JV; Wilcox PG; Ryerson CJ
Respir Med; 2017 Aug; 129():1-7. PubMed ID: 28732817
[TBL] [Abstract][Full Text] [Related]
34. Overall mortality in combined pulmonary fibrosis and emphysema related to systemic sclerosis.
Ariani A; Silva M; Bravi E; Parisi S; Saracco M; De Gennaro F; Caimmi C; Girelli F; De Santis M; Volpe A; Lumetti F; Hax V; Bredemeier M; Alfieri V; Santilli D; Bodini FC; Lucchini G; Mozzani F; Seletti V; Bacchini E; Arrigoni E; Giuggioli D; Chakr R; Idolazzi L; Bertorelli G; Imberti D; Michieletti E; Paolazzi G; Fusaro E; Chetta AA; Scirè CA; Sverzellati N
RMD Open; 2019; 5(1):e000820. PubMed ID: 30886735
[TBL] [Abstract][Full Text] [Related]
35. Peripheral blood leucocyte telomere length is associated with progression of interstitial lung disease in systemic sclerosis.
Liu S; Chung MP; Ley B; French S; Elicker BM; Fiorentino DF; Chung LS; Boin F; Wolters PJ
Thorax; 2021 Dec; 76(12):1186-1192. PubMed ID: 34272332
[TBL] [Abstract][Full Text] [Related]
36. High Prevalence of Acute Exacerbation of Interstitial Lung Disease in Japanese Patients with Systemic Sclerosis.
Tomiyama F; Watanabe R; Ishii T; Kamogawa Y; Fujita Y; Shirota Y; Sugimura K; Fujii H; Harigae H
Tohoku J Exp Med; 2016 Aug; 239(4):297-305. PubMed ID: 27487743
[TBL] [Abstract][Full Text] [Related]
37. Understanding diagnostic pathways in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: A retrospective cohort study.
Assassi S; Shao N; Yin Z; Volkmann ER; Zoz DF; Leonard TB
Medicine (Baltimore); 2022 Aug; 101(32):e29993. PubMed ID: 35960051
[TBL] [Abstract][Full Text] [Related]
38. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.
Chauvelot L; Gamondes D; Berthiller J; Nieves A; Renard S; Catella-Chatron J; Ahmad K; Bertoletti L; Camara B; Gomez E; Launay D; Montani D; Mornex JF; Prévot G; Sanchez O; Schott AM; Subtil F; Traclet J; Turquier S; Zeghmar S; Habib G; Reynaud-Gaubert M; Humbert M; Cottin V
Arthritis Rheumatol; 2021 Feb; 73(2):295-304. PubMed ID: 32892515
[TBL] [Abstract][Full Text] [Related]
39. Value of a national administrative database to guide public decisions: From the système national d'information interrégimes de l'Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France.
Tuppin P; Rudant J; Constantinou P; Gastaldi-Ménager C; Rachas A; de Roquefeuil L; Maura G; Caillol H; Tajahmady A; Coste J; Gissot C; Weill A; Fagot-Campagna A
Rev Epidemiol Sante Publique; 2017 Oct; 65 Suppl 4():S149-S167. PubMed ID: 28756037
[TBL] [Abstract][Full Text] [Related]
40. Clinical phenotypes, hemodynamic characteristics and prognosis of Chinese patients with systemic sclerosis-associated precapillary pulmonary hypertension: a retrospective study.
Yuan YP; Yuan P; Su YL; Jiang R; Zhang R; He J; Qiu HL; Luo CJ; Liu JM; Gong SG; Wang L; Zhao QH
Clin Rheumatol; 2022 Jun; 41(6):1675-1686. PubMed ID: 35099674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
